Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Aclaris Therapeutics (ACRS) shares
Learn how to easily invest in Aclaris Therapeutics shares.
Aclaris Therapeutics is a biotechnology business based in the US. Aclaris Therapeutics stocks (ACRS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.79 – an increase of 3.7% over the previous week. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around $6.8 million.
How to buy shares in Aclaris Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ACRS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Aclaris Therapeutics?
- Has coronavirus impacted Aclaris Therapeutics shares?
- Aclaris Therapeutics shares summary
- Compare share dealing platforms
- Is Aclaris Therapeutics stock a buy or sell?
- Aclaris Therapeutics performance over time
- Aclaris Therapeutics's financials
- How volatile are Aclaris Therapeutics shares?
- Does Aclaris Therapeutics pay a dividend?
- Other common questions
Aclaris Therapeutics stock price (NASDAQ:ACRS)Use our graph to track the performance of ACRS stocks over time.
Aclaris Therapeutics shares at a glance
|Latest market close||$10.10|
|52-week range||$9.26 - $30.38|
|50-day moving average||$13.28|
|200-day moving average||$17.25|
|Wall St. target price||$34.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.55|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Aclaris Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Aclaris Therapeutics price performance over time
|1 week (2022-01-19)||-0.39%|
|1 month (2021-12-25)||N/A|
|3 months (2021-10-25)||N/A|
|6 months (2021-07-29)||-42.58%|
|1 year (2021-01-29)||-51.33%|
|2 years (2020-01-29)||642.65%|
|3 years (2019-01-29)||50.30%|
|5 years (2017-01-27)||26.93|
Aclaris Therapeutics financials
|Revenue TTM||$6.8 million|
|Gross profit TTM||$-27,989,000|
|Return on assets TTM||-21.71%|
|Return on equity TTM||-63.46%|
|Market capitalisation||$596.4 million|
TTM: trailing 12 months
Aclaris Therapeutics share dividends
We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.
Aclaris Therapeutics share price volatility
Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $9.26 up to $30.375. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.4921. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).
Aclaris Therapeutics overview
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. .
Aclaris Therapeutics in the news
Appeals court upholds California's right to enforce its net neutrality law while the FCC remains at a standstill
Ackman takes a big stake in Netflix, excited about company's long-term prospects
What to watch today: Stock futures turn positive, reversing big overnight losses
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Silver Spike Investment Corp. (SSIC) stock in Canada when it goes public
Everything we know about the Silver Spike Investment Corp. IPO, plus information on how to buy in.
How to buy MOD Pizza stock in Canada when it goes public
Everything we know about the MOD Pizza IPO, plus information on how to buy in.
How to buy Modular Medical (MODD) stock in Canada when it goes public
Everything we know about the Modular Medical IPO, plus information on how to buy in.
How to buy Direct Digital Holdings (DRCT) stock in Canada when it goes public
Everything we know about the Direct Digital Holdings IPO, plus information on how to buy in.
How to buy TC BioPharm (TCBP) stock in Canada when it goes public
Everything we know about the TC BioPharm IPO, plus information on how to buy in.
How to buy Maris-Tech Ltd (MTEK) stock in Canada when it goes public
Everything we know about the Maris-Tech Ltd IPO, plus information on how to buy in.
How to buy Phoenix Motor (PEV) stock in Canada when it goes public
Everything we know about the Phoenix Motor IPO, plus information on how to buy in.
How to buy Nauticus Robotics, Inc. (KITT) stock in Canada when it goes public
Everything we know about the Nauticus Robotics, Inc. IPO, plus information on how to buy in.
What is Mogo and how can you access its new trading platform, MogoTrade? Find out in our review.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.